Search
Search
Contact Lawson Research Institute
Contact us
For general information or Lawson-specific questions:
Phone: 519 646-6005
Email: @email
To reach a member of the Lawson/St. Joseph’s Communications team with a story idea or a media-related inquiry, contact:
Communication and Public Affairs
Phone: 519 646-6100 ext. 66034
Fax: 519 646-6215
Email: comdept@sjhc.london.on.ca
If you need to contact a communicator after office hours (Mon to Fri, 8:30 am to 4:30 pm), call Switchboard at 519 646-6100 and ask them to page the communicator on-call.
Directions and parking
The main office of Lawson Research Institute is located within St. Joseph's Hospital. You can find a map to St. Joseph's Hospital along with Parking information below.
Lawson Research Institute inside St. Joseph's Hospital
268 Grosvenor Street
London, Ontario, N6A 4V2
Parking options
For those planning to park at or near St. Joseph’s Hospital, please ensure you leave extra time to do so. Due to the high number of people coming for care at St. Joseph’s Hospital, our two parking garages located on Grosvenor Street and on Cheapside Street are often at capacity Monday to Thursday between 9:30 a.m. and 2 p.m. ‘Lot full’ signs are posted when the parking garage(s) are full. Metered parking is available on the streets around the hospital.
As parking availability isn’t guaranteed at or nearby the hospital, St. Joseph’s encourages patients and family caregivers to consider making alternate travel arrangements when coming to the hospital, such as using public transit, taxi or being dropped off and picked up. Drop off areas are available at Entrance 1 and 2 on Grosvenor Street and Entrance 4 on Cheapside Street.
St. Joseph’s recognizes the frustration the lack of parking availability may cause and apologizes for any inconvenience. Thank you for your patience and understanding while we seek solutions to this issue.
Grosvenor parking garage
Daily rate: Minimum rate of $4 for the first hour and then $2 increments every half hour to a maximum of $8.75 after 2 hours.
Monthly rate: $60.75
There are 989 parking spaces in the Grosvenor Street parking garage.
View a printable map of parking spaces at St. Joseph's Hospital, Grosvenor Street Parking Garage (including accessible spaces).
The parking garage entrance is located on Grosvenor Street, across the street from Grosvenor Entrance 1. The garage is connected to Mount Hope Centre for Long Term Care through the underground tunnel (take elevators at northwest corner of the garage, see below).
Tunnel access at St. Joseph's Hospital
When visiting St. Joseph's Hospital and parking in the parking garage on Grosvenor Street the safest and most accessible route is through the tunnel. You can access the tunnel from the west end of the parking garage (closest to Richmond Street) by taking the elevators or stairs to level "B". When returning to your vehicle from Zone A you will need to push "T" (for tunnel) in the elevator.
Parking pay stations
Parking pay stations are located on the ground floor of both elevator lobbies located at the north-west and north-centre area of garage.
Pay stations only accept coins and credit cards. To purchase a monthly pass visit the Parking Garage office on the Wellington Street side of the Grosvenor Street Parking Garage, ground floor.
For further information, please call the parking office at 519 646-6100 ext. 65113.
Parking office hours are 8 am to 4 pm, Monday to Friday. Outside those hours, calls are directed to Precise ParkLink Inc. at 1-888-783 PARK (7275). The call centre can also be reached by intercom available on the parking pay machines in the garage's elevator lobby.
Accessible parking spaces
Accessible parking is available on each floor of the Grosvenor Street parking garage at the west end of the garage (closest to the Richmond and Grosvenor Street corner.) These parking spots are located close to the elevator that will take you to the wheelchair-accessible ramp on street level (level 1) or the underground tunnel that connects to both Mount Hope Centre for Long Term Care and St. Joseph’s Hospital.
Limited spots for accessible parking is also available on Wellington Street and on Grosvenor Street across from the Urgent Care Centre entrance (Entrance 2).
Cheapside parking garage
There are 132 parking spaces in the Cheapside Street parking garage.
View a printable map to parking spaces at St. Joseph's Hospital, Cheapside Street Parking Garage (including accessible spaces).
This is the closest lot for outpatients with appointments in Zones C and D of the hospital (Medical Imaging, Roth McFarlane Hand and Upper Limb Centre, Hand Therapy, Breast Care Centre, Rheumatology Centre, Physiotherapy Therapy, Occupational Therapy, WSIB Specialty Clinic, Shuttleworth Auditorium).
The entrance to the lot is on Cheapside Street just east of Richmond. It is open from 5:30 am to 5:30 pm, Monday to Friday, and closed on weekends. The elevator in the garage connects directly with the Francis and Madeleine Saul Medical Imaging Centre (Level 0) and the G. A. Huot Surgical Centre (Level 1). For appointments in Zone D, exit the parking garage elevator on Level 0 and walk across the lobby to the west side.
The parking pay station is located by the main elevators next to the gift shop in the Zone C lobby.
Parking meters at St. Joseph's Hospital
There are many city parking meters located within walking distance to St. Joseph's Hospital.
Rates are posted on the meters.
Street parking at St. Joseph's Hospital
Some of the residential streets that are within walking distance to the health centre offer one or two hour parking. Overnight parking is not permitted.
Please be courteous and do not block driveways.
Courteous parking to ensure maximum lot capacity
Please be aware that the City of London enforces parking regulations across all of St. Joseph’s sites to ensure patients, visitors, staff and physicians have adequate parking. All users of our parking facilities are asked to pay attention to parking regulations and how you park your vehicle.
As well, those who park for more than 10 minutes in patient drop-off designated areas, in handicapped parking without a permit, at loading docks, and other restricted areas will also find their vehicles being ticketed.
Thank you for respecting our parking regulations. If you have any parking questions please contact Precise ParkLink Inc.
Email: @email
Phone: 1-888-783 PARK (7275)
Public transit to St. Joseph's Hospital
St. Joseph's Hospital is conveniently located in a central location, with easy access to public transportation. Bus stops are located along Richmond Street and close to the Cheapside Street entrances. Contact the London Transit Commission at 519 451-1347 for rates and times.
The following London Transit bus routes will drop you off near entrances to St. Joseph's, see the London Transit trip planner and route schedules and real time LTC bus route tracking for more information:
- 6 Richmond
- 13 Wellington
- 1 Kipps Lane
- 21 Huron Heights
St. Joseph's is also just a few blocks north of Oxford Street, providing easy access from the Oxford St. bus routes.
Controlled-release opioid may be leading to heart infections in persons who inject drugs
A new study from ICES, Lawson Health Research Institute and Western University suggests that injection drug users prescribed controlled-release hydromorphone are three times more likely to develop endocarditis, a serious bacterial heart infection, when compared to those prescribed other opioids. The findings build on growing evidence that some controlled-release opioids may lead to higher risk of infectious disease among persons who inject drugs.
The researchers looked at de-identified Ontario health data for hospital admissions related to injection drug use between 2006 and 2015. Of 60,529 admissions, 733 patients had infective endocarditis. The team found that regions with high hydromorphone prescription rates had more than double the cases of infective endocarditis (254 cases) when compared to regions with low prescription rates (113 cases).
The study also analyzed individual prescription records and found that among persons who inject drugs, those prescribed controlled-release hydromorphone were three times more likely to develop infective endocarditis when compared to those prescribed any other opioid. There was no increased risk for those prescribed the immediate-release form of hydromorphone.
“Added to the existing data, these findings make a compelling argument for the role of controlled-release hydromorphone in the growing risk of infective endocarditis among persons who inject drugs,” says Dr. Matthew Weir, Adjunct Scientist at ICES, Associate Scientist at Lawson and Assistant Professor at Western’s Schulich School of Medicine & Dentistry.
Opioids are often manufactured as controlled-release or ‘slow-release’ capsules to prevent rapid absorption of the drug. Properties in the capsules help to spread pain relief over a longer period of time.
This is the latest in a series of studies from the research team that suggest some controlled-release opioids may be leading to increased risk of infectious disease among persons who inject drugs.
In one study, they demonstrated that polymer-coated beads used to provide the slow-release property make controlled-release hydromorphone difficult to dissolve. They found equipment used to dissolve the drug retains up to 45 per cent of the initial dose, leading injection drugs users to save and reuse equipment.
With frequent re-handling of equipment, there are multiple opportunities for bacterial and viral contamination. The team found that HIV and a dangerous bacterium called Staphylococcus aureus are more likely to survive in equipment used to prepare controlled-release hydromorphone since added chemicals that make the drug slow-release promote survival of bacteria and viruses.
“There’s been a global increase in infectious diseases among persons who inject drugs and our research suggests that controlled-release prescription opioids may be a major culprit,” says Dr. Michael Silverman, Associate Scientist at Lawson and Associate Professor at Schulich Medicine & Dentistry. “We now have evidence that suggests the injection of controlled-release hydromorphone is increasing the spread of HIV, hepatitis C and endocarditis in Canada.”
The team believes these findings could also explain the increase in infectious complications in the USA and other countries where controlled-release hydromorphone is not on the market. There are other controlled-release opioids, such as controlled-release morphine, that use a similar slow-release mechanism and may carry similar risks.
“It’s important that people are aware of the infectious risks of injecting opioids and, if necessary, practice harm reduction techniques,” says Dr. Silverman. “We’ve found you can use a cigarette lighter to destroy bacteria and viruses by heating the cooker used to prepare the drug for about 10 seconds or until the mixture bubbles. We’ve termed the technique ‘cook your wash.’”
The study, "Hydromorphone and the risk of infective endocarditis among people who inject drugs: a population-based, retrospective cohort study," was published in The Lancet Infectious Diseases.
Controlled-release opioid may be leading to heart infections in persons who inject drugs
LONDON, ON – A new study from ICES, Lawson Health Research Institute and Western University suggests that injection drug users prescribed controlled-release hydromorphone are three times more likely to develop endocarditis, a serious bacterial heart infection, when compared to those prescribed other opioids. The findings, published today in The Lancet Infectious Diseases, build on growing evidence that some controlled-release opioids may lead to higher risk of infectious disease among persons who inject drugs.
The researchers looked at de-identified Ontario health data for hospital admissions related to injection drug use between 2006 and 2015. Of 60,529 admissions, 733 patients had infective endocarditis. The team found that regions with high hydromorphone prescription rates had more than double the cases of infective endocarditis (254 cases) when compared to regions with low prescription rates (113 cases).
The study also analyzed individual prescription records and found that among persons who inject drugs, those prescribed controlled-release hydromorphone were three times more likely to develop infective endocarditis when compared to those prescribed any other opioid. There was no increased risk for those prescribed the immediate-release form of hydromorphone.
“Added to the existing data, these findings make a compelling argument for the role of controlled-release hydromorphone in the growing risk of infective endocarditis among persons who inject drugs,” says Dr. Matthew Weir, Adjunct Scientist at ICES, Associate Scientist at Lawson and Assistant Professor at Western’s Schulich School of Medicine & Dentistry.
Opioids are often manufactured as controlled-release or ‘slow-release’ capsules to prevent rapid absorption of the drug. Properties in the capsules help to spread pain relief over a longer period of time.
This is the latest in a series of studies from the research team that suggest some controlled-release opioids may be leading to increased risk of infectious disease among persons who inject drugs.
In one study, they demonstrated that polymer-coated beads used to provide the slow-release property make controlled-release hydromorphone difficult to dissolve. They found equipment used to dissolve the drug retains up to 45 per cent of the initial dose, leading injection drugs users to save and reuse equipment.
With frequent re-handling of equipment, there are multiple opportunities for bacterial and viral contamination. The team found that HIV and a dangerous bacterium called Staphylococcus aureus are more likely to survive in equipment used to prepare controlled-release hydromorphone since added chemicals that make the drug slow-release promote survival of bacteria and viruses.
“There’s been a global increase in infectious diseases among persons who inject drugs and our research suggests that controlled-release prescription opioids may be a major culprit,” says Dr. Michael Silverman, Associate Scientist at Lawson and Associate Professor at Schulich Medicine & Dentistry. “We now have evidence that suggests the injection of controlled-release hydromorphone is increasing the spread of HIV, hepatitis C and endocarditis in Canada.”
The team believes these findings could also explain the increase in infectious complications in the USA and other countries where controlled-release hydromorphone is not on the market. There are other controlled-release opioids, such as controlled-release morphine, that use a similar slow-release mechanism and may carry similar risks.
“It’s important that people are aware of the infectious risks of injecting opioids and, if necessary, practice harm reduction techniques,” says Dr. Silverman. “We’ve found you can use a cigarette lighter to destroy bacteria and viruses by heating the cooker used to prepare the drug for about 10 seconds or until the mixture bubbles. We’ve termed the technique ‘cook your wash.’”
-30-
DOWNLOADABLE MEDIA
Equipment used by persons who inject drugs
Cooker with lighter (demonstrating the ‘Cook your wash’ technique)
The Institute for Clinical Evaluative Sciences (ICES) is an independent, non-profit organization that uses population-based health information to produce knowledge on a broad range of health care issues. Our unbiased evidence provides measures of health system performance, a clearer understanding of the shifting health care needs of Ontarians, and a stimulus for discussion of practical solutions to optimize scarce resources. ICES knowledge is highly regarded in Canada and abroad, and is widely used by government, hospitals, planners, and practitioners to make decisions about care delivery and to develop policy. For the latest ICES news, follow us on Twitter: @ICESOntario
Lawson Health Research Institute is one of Canada’s top hospital-based research institutes, tackling the most pressing challenges in health care. As the research institute of London Health Sciences Centre and St. Joseph’s Health Care London, our innovation happens where care is delivered. Lawson research teams are at the leading-edge of science with the goal of improving health and the delivery of care for patients. Working in partnership with Western University, our researchers are encouraged to pursue their curiosity, collaborate often and share their discoveries widely. Research conducted through Lawson makes a difference in the lives of patients, families and communities around the world. To learn more, visit www.lawsonresearch.ca.
The Schulich School of Medicine & Dentistry at Western University is one of Canada’s preeminent medical and dental schools. Established in 1881, it was one of the founding schools of Western University and is known for being the birthplace of family medicine in Canada. For more than 130 years, the School has demonstrated a commitment to academic excellence and a passion for scientific discovery.
Senior Media Relations Consultant
Communications & Public Engagement
T: 519-685-8500 ext. 73502
Celine.zadorsky@lhsc.on.ca